ISRCTN59358441
Completed
Not Applicable
Interferon (IFN) induction followed by PEG-interferon combined with ribavirin and amantadine for treatment of naive chronic hepatitis C patients with genotype 1 or 4
Academic Medical Centre (AMC) (Netherlands)0 sites58 target enrollmentApril 4, 2006
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Hepatitis C virus (HCV)
- Sponsor
- Academic Medical Centre (AMC) (Netherlands)
- Enrollment
- 58
- Status
- Completed
- Last Updated
- 11 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Patients which are serum HCV\-RNA positive by PCR and with genotype 1 or 4
- •2\. Patients who never have used antiviral therapy for chronic hepatitis C
- •3\. Male and female patients \=18 and \<65 years of age
- •4\. Patients who have given written informed consent after a detailed explanation of the study by the investigator
Exclusion Criteria
- •1\. Patients who are pregnant and patients (male or female) who are not willing to practice adequate contraception during the treatment period and up to 6 months after ending the treatment period
- •2\. Patients who are HBsAg or human immunodeficiency virus (HIV) antibody positive or who are unwilling to have these tests done
- •3\. Patients with decompensated cirrhosis (e.g. albumin \<32 g/l, PTT prolonged \>4 s, bilirubin 2 x upper limit of normal, AT III \<60%, ascites, gastrointestinal \[GI] bleeding, encephalopathy)
- •4\. Patients with a history of intravenous (iv) drug use within 6 months prior to entry
- •5\. Patients with any clinically significant systemic disease other than liver disease (e.g. malignant disease, congestive heart failure, uncontrolled diabetes mellitus, renal failure (serum creatinine \>181 µmol/ml), or autoimmmune disease
- •6\. Patients with a history of auto\-immune hepatitis
- •7\. Patients using immune modulating treatment during the 6 months prior to study entry
- •8\. Patients with a history of hypersensitivity to any component of the study drugs
- •9\. Patients with pre\-existing bone marrow depression such as hematocrit \<32%, white blood cell count \<3\.0 x 10^9/l, granulocytes \<1\.5 x 10^9/l, platelets \<100 x 10^9/l, neutrophil count \<1\.5 x 10^9 or Hemoglobin \<8\.1 mmol/l for males and \<7\.0 mmol/l for females
- •10\. Patients with severe depression or other psychiatric illness
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Interferon induction followed by PEG-interferon combined with ribavirin and amantadine for treatment of naive chronic hepatitis C patients with genotype 1 or 4.chronic hepatitis CNL-OMON27278AMC Liver Center, Department GastroAcademic Medical Center, University of Amsterdam58
Completed
Phase 4
Efficacy and safety of PEG-Inferon (peginterferon alpha-2b) for the treatment of chronic hepatitis C - An open-label study in India.Health Condition 1: B182- Chronic viral hepatitis CCTRI/2011/091/000028Virchow Biotech100
Unknown
Phase 4
Efficacy and safety of PEG-Inferon (peginterferon alpha-2b) for the treatment of chronic hepatitis C - An open-label study in India.Health Condition 1: B182- Chronic viral hepatitis CCTRI/2015/02/005494Virchow Biotech Pvt Ltd
Recruiting
Not Applicable
Peginterferon or conventional interferon sequential entecavir treatment for hepatitis B e antigen positive chronic hepatitis B patients: a prospective randomized controlled trialchronic hepatitis BJPRN-UMIN000011666Toranomon Hospital100
Unknown
Phase 1
Pegylated Interferon and Entecavir Combination in Chronic Hepatitis B (CHB)Chronic Hepatitis BNCT01589952Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh20